首页 › 基金 › Foresite Capital Management IV, LLC › XENE
Foresite Capital Management IV, LLC 对 XENE 的持仓历史
XENON PHARMACEUTICALS INC · 医疗保健
Foresite Capital Management IV, LLC 在 Q3 2026 的 13F 申报中披露持有 XENE(XENON PHARMACEUTICALS INC)160,000 股,市值约 US$6.0M,约占其申报组合的 2.36%,在其申报持仓中市值排名第 6 位。 Foresite Capital Management IV, LLC 最近 6 个申报季度中有 6 个季度披露了 XENE 持仓,最早可追溯至 Q2 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Foresite Capital Management IV, LLC 对 XENE 的持仓演变
Foresite Capital Management IV, LLC 于 Q2 2025 首次披露 XENE 持仓:160,000 股(约 US$5.0M)。 该持仓在 Q2 2026 达到峰值 160,000 股,市值约 US$9.7M。 在 6 次申报中,Foresite Capital Management IV, LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 160,000 股、市值约 US$6.0M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2025 | 160.00K | $5.01M | 新进 |
| Q3 2025 | 160.00K | $6.42M | 持有 |
| Q4 2025 | 160.00K | $7.17M | 持有 |
| Q1 2026 | 160.00K | $9.30M | 持有 |
| Q2 2026 | 160.00K | $9.66M | 持有 |
| Q3 2026 | 160.00K | $5.95M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 XENE 与 13F 数据
XENE(XENON PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 26 只申报持有 XENE,申报仓位最大的包括:Avoro Capital Advisors LLC (US$204.5M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), Affinity Asset Advisors, LLC (US$70.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 XENE 的基金
- Avoro Capital Advisors LLC 5.50M 股 · $204.54M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 3.56M 股 · $132.31M · Q3 2026
- Affinity Asset Advisors, LLC 1.90M 股 · $70.67M · Q3 2026
- BRAIDWELL LP 1.71M 股 · $63.54M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M 股 · $60.09M · Q3 2026
- ADAR1 Capital Management, LLC 1.16M 股 · $43.22M · Q3 2026
更多关于 Foresite Capital Management IV, LLC
常见问题
How long has Foresite Capital Management IV, LLC held XENE?
Foresite Capital Management IV, LLC has disclosed XENE holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Foresite Capital Management IV, LLC's current position in XENE?
As of Q3 2026, Foresite Capital Management IV, LLC holds 160.00K shares of XENE (XENON PHARMACEUTICALS INC), valued at $5.95M, representing 2.36% of its reported portfolio and ranking #6.
Has Foresite Capital Management IV, LLC been buying or selling XENE?
In the latest 13F filing (Q3 2026), Foresite Capital Management IV, LLC held unchanged its position in XENE. The position peaked in Q2 2026 at 160.00K shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Affinity Asset Advisors, LLC, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.